Clinical Trial Search

Primary: Percentage of Participants With Kaplan-Meier Curve Progression Free Survival (PFS) Constructed With an 95% Confidence Interval — 100; 82.1; 71.0 percentage of participants

Primary: Complete Remission Rate: Percentage of Participants With Complete Remission (CR) — 85 percentage of participants

Primary: Overall Survival (OS) at 1 Year — 1.0; 0.82 Cumulative proportion surviving at 1 yr

Primary: Participants With a Response — 9 Participants

Primary: Complete Response Rate — 83 percentage of participants

Primary: Overall Response Rate (ORR) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen — 100; 100; 100; 100 percentage of patients

Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects

Primary: Overall Response Rate — 11; 2 Participants

Primary: Complete Remission — 10 participants

Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035

Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants

Primary: Participants With Treatment-Emergent (Blinatumomab) Adverse Events — 28; 11; 5; 7 Participants

Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients

Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants

Primary: Overall Response Rate (ORR) — 0.05 Proportion of participants

Primary: Percentage of Participants With a Complete Remission (CR) or Partial Remission (PR) — 39.5 percentage of participants

Primary: Treatment-related Mortality Within 30 Days (TRM30) — 0 Participants

Primary: Overall Response (OR) Rate — 36 Participants

Primary: Progression-free Survival — 72 Percent

Primary: Overall Response Rate (ORR) as Determined by Local Investigator — 32.1 Percentage of participants

Primary: Overall Response (OR) Rate — 0.07 Proportion of participants

Primary: To Evaluate the Overall Response Rate (ORR) of Brentuximab Vedotin in EBV- and CD30-positive Lymphomas — 12 Participants

Primary: R-IPI Index (Revised International Prognostic Index) — 3.4; 32.2; 64.4 percentage of participants

Primary: Clinical Response Rate — 2; 0; 1; 1 participants

Primary: Overall Response Rate (ORR) — 46.2 percentage of participants — p=0.0044

Primary: 1-year Progression-free Survival — 31 Participants

Primary: Event-free Survival (EFS) — 83 percentage of not experiencing EFS event

Primary: Group 2, RRHL: Progression Free Survival (PFS) — 13.17 months

Primary: Proportion of Responses (Complete Response or Partial Response) — 19.0; 42.9 percentage of participants

Primary: Time to Rituximab Failure (TTRF) — 3.92; 4.32; 1.39; 4.83 years — p=0.33